$1.25
-0.02 (-1.57%)
Open$1.24
Previous Close$1.27
Day High$1.29
Day Low$1.15
52W High$2.40
52W Low$1.02
Volume—
Avg Volume100.6K
Market Cap33.38M
P/E Ratio—
EPS$-2.63
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,656.0% upside
Current
$1.25
$1.25
Target
$46.95
$46.95
$33.28
$46.95 avg
$64.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.89M | 42.94M | 46.10M |
| Net Income | 949.8K | 770.7K | 699.4K |
| Profit Margin | 2.0% | 1.8% | 1.5% |
| EBITDA | 1.44M | 1.43M | 1.37M |
| Free Cash Flow | 717.1K | 500.4K | 604.2K |
| Rev Growth | -0.9% | +8.9% | +4.5% |
| Debt/Equity | 0.33 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |